Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →

This Solicitation opportunity from Government of Canada was posted on December 15, 2023. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Single-Use Bioreactor with a 50L working volume

Closed
23-58179Canada

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Government of Canada → National Research Council CanadaView Agency

NAICS

N/A

Place of Performance

*Quebec (except NCR), CAN

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyGovernment of Canada → National Research Council Canada
Contacts1 person available
OfficeN/A
Organization / Agency
Government of Canada → National Research Council Canada
View Agency Profile
Office AddressN/A
Contacts
Kacendra DionPoint of Contact

Full Description

Show more
The National Research Council Canada (CCSU) team has a requirement for the purchase of a single-use bioreator with a 50L working volume. They are dedicated to the development and scale-up of processes necessary for the cost-effective production of vaccines and protein drug products within a Research & Development environment that has less constraints than GMP environments, which lower development costs. The CCSU team play a role in de-risking GMP production by transferring the processes to GMP facilities.